Lantern Pharma Inc. (LTRN) received a notice from The Nasdaq Stock Market on September 25, 2026, indicating that the company is not in compliance with the minimum market value of listed securities (MVLS) requirement for continued listing on the Nasdaq Capital Market.
Key Details
- Non-Compliance Issue: The company's MVLS fell below the required minimum of $35 million for 30 consecutive business days, violating Nasdaq Listing Rule 5550(b)(2).
- Compliance Period: Lantern Pharma has a 180-calendar day period, until March 24, 2027, to regain compliance.
- Regaining Compliance: To resolve the issue, the company's MVLS must close at or above $35 million for a minimum of 10 consecutive business days within the compliance period. Failure to do so could result in delisting proceedings.